Skip to NavigationSkip to content

Syntimmune

Syntimmune appoints Pfizer, AbbVie veteran as new CMO

Published on: 10/07/18

The Boston-based clinical biotechnology company Syntimmune has appointed Dr Mario Saltarelli as its Chief Medical Officer. Dr Saltarelli will take the role of current CMO Dr Donald Johns who will become the Executive Vice President of Medical and Scientific Affairs for Syntimmune.

Having earned both an MD and PhD in neurosciences from John Hopkins University School of Medicine, Dr Saltarelli brings to the role a variety of expertise developed through experiences in discovery research, clinical development, pipeline strategy and global regulatory operations.

Syntimmune brings in new CEO from Biogen

Published on: 04/01/18

Syntimmune has revealed that it has brought in a new CEO to begin the new year, with the appointment of Jean-Paul Kress. He leaves behind his position as EVP, President International and Head of Global Therapeutic Operations at Biogen, after only eight months in the position, to take the helm.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches